Who We Are
ReGenTree, LLC is a newly created U.S. joint venture company owned by HLB Therapeutics (formerly GtreeBNT Co., Ltd.), a bio venture company in Korea and by RegeneRx Biopharmaceuticals, Inc., a clinical stage drug development company in the USA. As of January 2015, ReGenTree is developing a novel therapeutic peptide, RGN-259 (designated GBT-201 in Korea), in the USA for ophthalmic indications.
HLB Therapeutics holds a major equity stake in ReGenTree and is responsible for conducting and funding all clinical trials and product development. RegeneRx contributes all of its related intellectual property and non-clinical and clinical data generated to date.
ReGenTree seeks to become a top pharmaceutical company specializing in ophthalmology. It is currently conducting two Phase III clinical trials in the USA to develop treatments for dry eye syndrome and for neurotrophic keratopathy (a rare disease with orphan designation by the USA FDA) with RGN-259/GBT-201. RGN-259/GBT-201 is a sterile, preservative-free eye drop formulation with Blow-Fill-Seal technology that has the novel compound thymosin beta 4 (Tβ4) as its active pharmaceutical ingredient.